ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 870

Off-Label Use of Biotherapies to Treat Relapsing And/or Refractory Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss)

Alice Canzian 1, Nils Venhoff 2, Silvia Sartorelli 3, Anne-Marie Ruppert 4, Matthieu Groh 5, Camille Taille 6, Virginie Rieu 7, Perrine Smets 7, François Maurier 8, Nicolas Girszyn 9, Maxime Samson 10, Claire de Moreuil 11, Grégory Pugnet 12, Xavier Delbrel 13, Jean-Emmanuel Kahn 14, Xavier Puéchal for the French Vasculitis Study Group 15, Giacomo Emmi 16, Loic Guillevin 15, Lorenzo Dagna 17, Jens Thiel 2, Augusto Vaglio 18 and Benjamin Terrier15, 1Cochin Hospital, Paris, France, 2Clinic for Rheumatology and Clinical Immunology, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg, Germany, 3Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy, 4Tenon Hospital, Paris, France, 5Service de Médecine Interne, Centre de Référence des Syndromes Hyperéosinophiliques-CEREO, Hôpital Foch, Université Versailles–Saint-Quentin-en-Yvelines, Suresnes, France, Suresnes, France, 6Bichat Hospital, Paris, France, 7CHU, Clermont-Ferrand, France, 8Service de Médecine Interne, Hôpital Belle Isle, Metz, Metz, France, 9CHU, Rouen, France, 10Service de Médecine Interne et Immunologie Clinique, CHU Dijon Bourgogne, Hôpital François Mitterrand, Dijon ; Université Bourgogne-Franche Comté, INSERM, EFS BFC, UMR1098, F-21000 Dijon, Dijon, France, 11CHU Brest, Brest, France, 12CHU de Toulouse, Hôpital Purpan, Service de Médecine Interne, Toulouse, France, 13CH, Pau, France, 14APHP, Boulogne Billancourt, France, 15National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, 16Department of Experimental and Clinical Medicine, University of Firenze, Florence, Italy, Florence, Italy, 17Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy, 18Nephrology Unit, Parma University Hospital, Parma, Italy, Nephrology Unit, Parma University Hospital, Parma, Italy, Italy

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Churg-Strauss syndrome, systemic vasculitides and Biologic agents

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 10, 2019

Session Title: 3S085: Vasculitis – ANCA-Associated I (869–874)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg–Strauss syndrome), is characterized by small-vessel necrotizing vasculitis, and blood and tissue eosinophilia in asthmatic individuals. Glucocorticoids (GCs) usually control EGPA, but vasculitis relapses and GC-dependent asthma are frequent, as are long-term adverse events, leading to potential biotherapy use. We examined off-label biological therapy use for relapsing/refractory EGPA.

Methods:

This retrospective European collaborative study included patients with EGPA, meeting the ACR criteria and/or Chapel Hill Consensus Conference definitions. Treatment efficacy and safety were recorded. Remission was defined as the absence of asthma, sinonasal and vasculitis manifestations with ≤5 mg/day of prednisone, and partial response as the absence of manifestations but requiring 6–10 mg/day of prednisone.

Results:

Among the147 patients (74 men, 73 women; median age 52 years) included, 63 (43%) received rituximab (RTX), 51 (35%) mepolizumab (MEPO), at monthly respective doses of 100 mg or 300 mg for 29 (57%) and 22 (43%), and 33 (22%) omalizumab (OMA). Previous treatments were: GCs for all, azathioprine (68%), cyclophosphamide (40%), methotrexate (29%) or mycophenolate mofetil (15%).

At inclusion, median (interquartile range) BVAS in the RTX, OMA and MEPO groups, respectively, were 8.5 (5-13), 2 (2-5) and 2 (2-6). In the RTX-treated patients, median BVAS fell to 1 (0-4.5) at 6 and 0 (0-2) ay 12 months.A Median GCs dose decreased to 7.5 (5-10) at 6 months and 12 months. Overall, remissions, partial responses, therapeutic failure and stop for adverse event, respectively, were noted in 49%, 24%, 24% and 3% for RTX recipients. Remission was observed in 57% of ANCA-positive patients compared to 42% in ANCA-negative patients.

To treat GC-dependent asthma, MEPO had a much better GCs-sparing effect than OMA, and a better overall response. Remissions, partial responses, therapeutic failure and stop for adverse event, respectively, were noted in 15%, 33%, 48% and 4% for OMA recipients and 78%, 10%, 8% and 4% for MEPO recipients.Finally, no obvious difference was noted between patients receiving MEPO 100 mg and those 300 mg monthly, in terms of GC-sparing effect and overall response.

Sixteen (25%) patients stopped RTX: 2 for adverse events, and 14 for refractory disease. Also, 17 (27%) experienced adverse events, mainly severe infections. Seventeen (52%) stopped OMA:  1 for severe infusion reaction, and 16 for refractory disease. Four (12%) patients receiving OMA experienced mild to moderate adverse events. Three (6%) patients stopped MEPO: 2 for adverse events (one severe infusion reaction and one because of paraesthesia), and 1 for pregnancy. Eleven (22%) patients receiving MEPO experienced mild to moderate adverse events, mainly asthenia.

Conclusion: These results suggest that RTX could be effective for 50% of patients with EGPA vasculitis relapses, with an acceptable safety profile. MEPO is highly effective with a good GCs-sparing effect and safety profile in patients with GCs-dependant asthma, and 100 mg monthly seems to be an acceptable dose at first-line.


Disclosure: A. Canzian, None; N. Venhoff, Novartis, 2, 5; S. Sartorelli, None; A. Ruppert, None; M. Groh, None; C. Taille, None; V. Rieu, None; P. Smets, None; F. Maurier, None; N. Girszyn, None; M. Samson, None; C. de Moreuil, None; G. Pugnet, None; X. Delbrel, None; J. Kahn, None; X. Puéchal for the French Vasculitis Study Group, LFB, 8, Pfizer, 2, 8, Roche, 8; G. Emmi, None; L. Guillevin, None; L. Dagna, AbbVie, 5, Amgen, 5, Biogen, 5, Bristol-Myers Squibb, 5, Celltrion, 5, Novartis, Pfizer, 5, Sanofi-Genzyme, 5, SOBI, 2, 5; J. Thiel, Novartis Pharma GmbH, 2, 5; A. Vaglio, None; B. Terrier, Grifols, 8, GSK, 8, LFB, 8, Roche, 8.

To cite this abstract in AMA style:

Canzian A, Venhoff N, Sartorelli S, Ruppert A, Groh M, Taille C, Rieu V, Smets P, Maurier F, Girszyn N, Samson M, de Moreuil C, Pugnet G, Delbrel X, Kahn J, Puéchal for the French Vasculitis Study Group X, Emmi G, Guillevin L, Dagna L, Thiel J, Vaglio A, Terrier B. Off-Label Use of Biotherapies to Treat Relapsing And/or Refractory Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss) [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/off-label-use-of-biotherapies-to-treat-relapsing-and-or-refractory-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/. Accessed April 13, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/off-label-use-of-biotherapies-to-treat-relapsing-and-or-refractory-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.